Core Insights - Roche announced five-year efficacy, safety, and durability data for Susvimo® (ranibizumab injection) in treating neovascular age-related macular degeneration (nAMD), showing sustained treatment effects with approximately 95% of patients requiring no supplemental treatment before each refill [1][6]. Efficacy and Safety Data - The Phase III Portal study demonstrated that Susvimo maintained vision and retinal drying over five years, with best-corrected visual acuity (BCVA) in the Susvimo cohort decreasing from 74.4 letters at baseline to 67.6 letters at five years, while the IVT-Susvimo cohort showed a decrease from 76.3 letters to 68.6 letters [3][6]. - Average central subfield thickness (CST) remained stable, with a reduction of 1.0 µm in the Susvimo cohort and 10.3 µm in the IVT-Susvimo cohort [3]. Study Design and Population - The Portal study followed a cohort of 352 patients, with 220 receiving Susvimo refills every six months and 132 transitioning from monthly intravitreal (IVT) injections to Susvimo [2][5]. - The Archway study, which preceded the Portal study, was a randomized, multicenter trial involving 415 patients, comparing Susvimo to monthly IVT ranibizumab injections [5]. Treatment Mechanism - Susvimo utilizes a refillable eye implant that continuously delivers a customized formulation of ranibizumab, contrasting with other treatments that may require monthly injections [4][9]. - This delivery system aims to provide a more consistent treatment regimen, potentially leading to better real-world outcomes for patients with nAMD [2][4]. Industry Context - nAMD is the leading cause of vision loss in individuals over 60, affecting approximately 20 million people globally, with numbers expected to rise as the population ages [8]. - The innovative approach of Susvimo positions Roche as a leader in the treatment of nAMD, addressing a significant unmet need in the market [6][9].

Core Insights - Roche announced five-year efficacy, safety, and durability data for Susvimo® (ranibizumab injection) in treating neovascular age-related macular degeneration (nAMD), showing sustained treatment effects with approximately 95% of patients requiring no supplemental treatment before each refill [1][2][7] Group 1: Study Results - The Phase III Portal study demonstrated that Susvimo maintained vision and retinal drying over five years, with best-corrected visual acuity (BCVA) showing a decline from 74.4 letters at baseline to 67.6 letters at five years in the Susvimo cohort, and from 76.3 letters to 68.6 letters in the IVT-Susvimo cohort [3][4] - Average central subfield thickness (CST) remained stable, with a reduction of 1.0 µm in the Susvimo cohort and 10.3 µm in the IVT-Susvimo cohort [3] Group 2: Treatment Comparison - Susvimo provides continuous delivery of ranibizumab via a refillable eye implant, contrasting with other treatments that may require monthly injections [5][10] - The Portal study cohort is the largest group of nAMD patients followed prospectively for five years, enhancing the reliability of the results [4][6] Group 3: Clinical Implications - The long-term results support Susvimo's potential to preserve vision in nAMD patients, addressing the challenges of frequent injections associated with traditional anti-VEGF treatments [2][7] - The study's findings may lead to improved real-world clinical outcomes for patients with nAMD, as continuous delivery could offer better vision preservation compared to standard treatments [2][6]